TABLE 1.
Meta‐analysis studies of postoperative outcomes in patients with CD treated with anti‐TNF agents
| Authors | Type of complication | No. studies included | Study population | Experiment | Anti‐TNF group complication rate (%) | Non‐anti‐TNF group complication rate (%) | OR (CI) |
|---|---|---|---|---|---|---|---|
| Kopylov et al 82 |
Overall Infectious Noninfectious |
6 6 4 |
1316 1159 834 |
Anti‐TNF‐α agents |
142/336 (42) 78/287 (27) 39/200 (20) |
284/980 (30) 165/872 (19) 60/634 (9) |
1.72 (0.93–3.19) 1.50 (1.08–2.08) 1.26 (0.65–2.42) |
| Billioud, et al 83 |
Overall Infectious |
6 7 |
1316 1699 |
Anti‐TNF‐α agents |
85/336 (25) 99/484 (21) |
196/980 (20) 169/1215 (14) |
1.31 (0.96–1.77) 1.45 (1.03–2.05) |
| Narula et al 87 |
Infectious Non‐infectious Total |
15 11 13 |
3244 2496 3840 |
Anti‐TNF‐α agents |
214/987 (22) 227/813 (28) 464/1059 (44) |
328/2257 (15) 316/1683 (9) 801/2781 (29) |
1.56 (1.09–2.24) 1.57 (1.14–2.17) 1.73 (1.23–2.43) |
| Rosenfeld et al 86 |
Major Minor Repeat operation |
6 3 3 |
1129 564 710 |
Infliximab |
99/257 (39) 25/148 (17) 18/173 (10) |
223/872 (26) 17/416 (4) 29/537 (5) |
1.59 (0.89–2.86) 1.80 (0.87–3.71) 1.33*0.55–3.30 |
| El‐Hussuna et al 88 | All anastomotic |
13 11 |
2046 2340 |
Anti‐TNF‐α agents |
238/419 (57) 45/593 (8) |
589/1627 (36) 143/1747 (8) |
1.25 (1.10–1.43) 0.91 (0.56–1.47) |
| Yang et al 89 |
Total Infectious |
13 10 |
2538 2116 |
Infliximab |
235/663 (35) 168/626 (27) |
479/1875 (26) 280/1490 (19) |
1.45 (1.04–2.02) 1.47 (1.08–1.99) |
| Ali et al 75 |
Total Infectious |
7 12 |
1454 3057 |
Anti‐TNF‐α agents |
235/431 (55) 152/823 (18) |
192/1023 (19) 317/2234 (14) |
1.16 (0.97–1.40) 1.29 (1.07–1.55) |
| Huang et al 74 | Septic | 6 | 1833 | Anti‐TNF‐α agents | Not reported | Not reported |
1.29 (0.79–2.11) |
| Waterland et al 92 |
Total infectious Abdominal sepsis |
8 9 |
1782 3988 |
Infliximab |
165/548 (30) 60/697 (9) |
252/1234 (20) 148/3291 (4) |
1.52 (1.14–2.03) 1.22 (0.87–1.72) |
| Lin et al 90 |
Total Infectious |
20 15 |
7159 7063 |
Anti‐TNF agents |
476/1673 (28) 272/1625 (17) |
1086/5486 (20) 461/5438 (8) |
1.53 (1.11–2.09) 2.09 (1.19–3.65) |
| Xu et al 84 |
Overall Infectious |
16 14 |
5498 5179 |
infliximab |
619/1309 (47) 301/1244 (24) |
1064/4189 (25) 485/3935 (12) |
1.17 (0.82–1.66) 1.23 (0.87–1.74) |
| Law et al 91 | Total | 27 | Not reported | Anti‐TNF Agents | Not reported | Not reported | 1.43 (1.09–1.87] |
| Hanzel et al 85 |
Total Infectious |
6 6 |
1224 1721 |
Anti‐TNF Agents |
179/447 (40) 112/694 (16) |
207/777 (27) 93/1027 (9) |
1.03 (0.71–1.51) 2.05 (1.40–3.01) |